Abstract: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating the culture with a p70 S6 kinase inhibitor. The resulting cells are useful in the treatment of immune-related diseases.

Abstract: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating with a PI-3K antagonist. The resulting cells are useful in the treatment of immune-related diseases.

Abstract: Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while minimizing the production of IL-17. The resulting cells are useful in the treatment of immune-related diseases.

Abstract: The present invention provides drug formulations and methods that comprise omega-3 and/or omega-6 fatty acids, and their ester derivatives (e.g., methyl, ethyl, isopropyl, etc.), which are soluble in non-CFC propellants. The addition of omega-3 or omega-6 fatty acids to the aerosol formulations also provides therapeutic benefits.

Abstract: A video game distribution network for use in airlines, trains, hotels, cruise ships, set top boxes, cable television systems, satellite and other wireless systems or other communications systems, distributes special purpose game binary image files to general purpose computing/display devices. Software emulators running on the general purpose computing/display devices model the game source platform and interpret and/or compile the game files to provide interactive video game play. Software emulators for emulating a handheld video game platform such as GAME BOY®, GAME BOY COLOR® and/or GAME BOY ADVANCE® on a low-capability target platform (e.g., a seat-back display for airline or train use, a personal digital assistant, a cell phone) may provide any number of features and optimizations to provide high quality graphics and sound that nearly duplicates the game playing experience on the native platform.

Abstract: This invention relates to a method for the separation of stereoisomers of 7-hydroxy-furo[3,4-c]pyridine derivatives of the formula ##STR1## wherein R.sub.3, R.sub.4 and R.sub.6 represent various substitutents, which comprises reacting a fully O-acetylated monosaccharide halogenide with a racemate of the selected 7-hydroxy-furo[3,4-c]pyridine derivative, to form the (+) and (-) (O-acetylated monosaccharide) (furo[3,4-c] pyridine 7-yl derivative) ethers, then separating the (+) and the (-) ethers by selective crystallization, in an hydroalcoholic medium, either of the acetylated forms or of the corresponding desacetylated forms and, finally, working up each of the separated derivatives by the usual routes. The compounds are known pharmaceuticals.

Abstract: The invention relates to a method for the preparation of a non-racemic furo [3,4-c] pyridine derivatives of the formula I ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 stand for various substitutents, comprising adding a concentrated strong acid to a solution of a non-racemic compound of the formula II ##STR2## in an amount sufficient to catalyze a deprotection/cyclodehydration. These compounds are known antihypertensives.

Abstract: The present invention relates to stereospecific processes for the preparation of enantiomers of 3-substituted-furo[3,4-c]pyridine of formula I, wherein R.sub.3, R.sub.4 and R.sub.6 stand for various substituents, comprising the steps of: oxidation of a racemic pyridine derivative of formula II, reduction of the resulting ketone with a reducing agent, sterospecific locking or blocking of the OH group of the enantiomer alcohol, opening of the acetonide ring and cyclization of the resulting compound. ##STR1##The present invention also relates to compounds thus obtained and therapeutical compositions thereof.